Compare Cytokinetics Inc (CYTK) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Philip Morris International Inc. — how do they compare? Cytokinetics Inc trades at $81.35 (market cap $11.12B), while Philip Morris International Inc. trades at $176.41 (market cap $274.23B). The key difference: Philip Morris International Inc. is far larger — about 24.7× Cytokinetics Inc's market cap, and Philip Morris International Inc. pays a 3.34% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PM | |
|---|---|---|
Market Cap | $11.12B | $274.23B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $191.86 |
52-Week Low | $33.23 | $144.33 |
Enterprise Value | $11.59B | $320.73B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Philip Morris International (PM) trades at $180.19, down 0.79% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $194.00. The company reported strong Q1 2026 EPS of $1.96, beating expectations, and maintains robust profitability with a 26.74% net income margin. Recent news includes a $500 million impairment charge in Q2 2026 and CFO succession plans, while cash flow trends show stable operations.
The stock presents a favorable risk-reward profile with upside to analyst targets, driven by earnings beats and brand strength, though risks include currency volatility, regulatory pressures, and consumer spending constraints highlighted in recent Reuters and WSJ reports. Long-term investors may find value in its dividend yield and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
